Overreactive macrophages in SARS-CoV-2 infection: The effects of ACEI

Dominik Felkle1, Katarzyna Zięba1, Konrad Kaleta1

  • 1Students' Scientific Group at the Department of Immunology, Jagiellonian University Medical College, Czysta 18, 31-121 Kraków, Poland.

PubMed

Insights

Angiotensin-converting enzyme inhibitors (ACEI) may benefit COVID-19 patients by modulating macrophage activity, reducing severe disease risk. These drugs appear to mitigate the cytokine storm, offering a protective effect against severe SARS-CoV-2 complications.

Area of Science:

  • Immunology
  • Pharmacology
  • Virology

Background:

  • Macrophage overactivation drives the cytokine storm in severe COVID-19.
  • Concerns existed regarding ACE inhibitors (ACEI) due to increased ACE2 expression, a SARS-CoV-2 receptor.
  • Clinical observations suggest ACEI may be safe and beneficial in COVID-19 patients.

Purpose of the Study:

  • To review the dual role of macrophages in SARS-CoV-2 infection.
  • To elucidate the mechanisms behind the beneficial effects of ACEI on macrophages.
  • To explore how ACEI impacts macrophage response and COVID-19 severity.

Main Methods:

  • Review of current knowledge on macrophage function in COVID-19.
  • Analysis of the impact of ACE inhibitors on macrophage activation.
  • Examination of molecular pathways involving ACE2, angiotensin-(1-7), and macrophage receptors.

Main Results:

  • ACEI demonstrate beneficial effects on macrophages, promoting anti-inflammatory activation.
  • ACEI may reduce the risk of severe COVID-19 and life-threatening complications.
  • Proposed mechanisms include stimulation of angiotensin II type 2 and Mas receptors by angiotensin-(1-7) and direct inhibition of macrophage hyper-responsiveness.

Conclusions:

  • ACEI may exert protective effects in SARS-CoV-2 infection by modulating macrophage responses.
  • Targeting macrophages with ACEI could be a therapeutic strategy to mitigate COVID-19 severity.
  • Increased ACE2 expression on macrophages due to ACEI may enhance antiviral responses.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
687
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
776
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
677
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
476